Ravulizumab-cwvz (huarahi intravenous)

Ultomiris

Ko te werohanga Ravulizumab-cwvz hei whakaora i tetahi momo mate toto e kiia nei ko te paroxysmal nocturnal hemoglobinuria (PNH). Ko tenei rongoā hei whakaiti i te whakangaromanga o ngā pūtau toto whero, te pakaru rānei (hemolysis) i ngā tūmanako e pangia ana e te PNH. Ka whakamahia ano te werohanga Ravulizumab-cwvz hei whakaora i te atypical hemolytic uremic syndrome (aHUS) i ngā pakeke me ngā tamariki. Ka whakamahia ano te werohanga Ravulizumab-cwvz hei whakaora i tetahi raruraru o ngā io me ngā uaua e kiia nei ko te generalized myasthenia gravis (gMG) i ngā tūmanako e whai anti-acetylcholine receptor (AChR) antibody pai ana. Ka whakamahia ano te werohanga Ravulizumab-cwvz hei whakaora i te neuromyelitis optica spectrum disorder (NMOSD), he mate onge e pā ana ki te mumura o ngā io o ngā kanohi me te iwi o muri. Ka whakamahia i ngā tūmanako e whai anti-aquaporin-4 (AQP4) antibody pai ana. Ko te werohanga Ravulizumab-cwvz he monoclonal antibody e mahi ana i runga i te pūnaha ārai mate. Kei te wātea noa tenei rongoā i raro i te kaupapa tohatoha whakawāiti e kiia nei ko te Ultomiris® REMS (Risk Evaluation and Mitigation Strategy) Program. Kei te wātea tēnei hua i ngā momo horoinga e whai ake nei:

I te whakatau ki te whakamahi i te rongoā, me whakarite te kino o te tango i te rongoā ki te pai ka puta mai. Koinei te whakatau ka mahia e koe me tō tākuta. Mō tēnei rongoā, me whakaarohia enei: Korero atu ki tō tākuta mēnā kua pāngia koe e tetahi āhuatanga rerekē, te mate pāwera rānei ki tēnei rongoā, ki ētahi atu rongoā rānei. Korero atu hoki ki tō kaimahi hauora mēnā kei a koe ētahi atu momo mate pāwera, pēnei i ngā kai, ngā tae, ngā whakaora, ngā kararehe rānei. Mō ngā hua kore-whakahaunga, panuihia te tohu, te whakauru rānei o te kete. Kāo te whakaatu i ngā rangahau tika kua oti i tēnei wā i ngā raruraru motuhake a ngā tamariki ka āhei te whakaiti i te whakamahinga o te werohanga ravulizumab-cwvz hei whakaora i te paroxysmal nocturnal hemoglobinuria (PNH) me te atypical hemolytic uremic syndrome (aHUS) i ngā tamariki 1 marama te pakeke me te pakeke ake. Heoi, kāo te whakapumautia te ora me te whai hua hei whakaora i te PNH me te aHUS i ngā tamariki i raro i te 1 marama te pakeke, te whakaora rānei i te generalized myasthenia gravis (gMG) me te neuromyelitis optica spectrum disorder (NMOSD) i ngā tamariki. Kāo te whakaatu i ngā rangahau tika kua oti i tēnei wā i ngā raruraru motuhake a ngā kaumātua ka āhei te whakaiti i te whakamahinga o te werohanga ravulizumab-cwvz i ngā kaumātua. Kāo he rangahau tika mō ngā wāhine hei whakatau i te tūponotanga o te pēpi ina whakamahi i tēnei rongoā i te wā e whāngai u. Whakaritehia ngā painga pea ki ngā tūponotanga pea i mua i te tango i tēnei rongoā i te wā e whāngai u ana. Ahakoa kāo te whakamahi tahi i ētahi rongoā, i ētahi atu take ka taea te whakamahi tahi i ngā rongoā rerekē e rua ahakoa ka puta mai he mahi tahi. I enei take, ka hiahia pea tō tākuta ki te whakarereke i te horo, te whakamahi rānei i ētahi atu whakatūpato. I te wā e whiwhi ana koe i tēnei rongoā, he mea nui rawa atu kia mohio tō kaimahi hauora mēnā kei te tango koe i tetahi o ngā rongoā kua whakarārangihia i raro nei. Kua tohua ngā mahi tahi e whai ake nei i runga i te nui o te āhuatanga, ā, kāo pea te katoa. Ko te whakamahi i tēnei rongoā me tetahi o ngā rongoā e whai ake nei kāo te tūtohutia, engari ka hiahiatia pea i ētahi wā. Mēnā kua tohua ngā rongoā e rua tahi, ka whakarereke pea tō tākuta i te horo, te maha rānei o te whakamahi i tetahi, i ngā rongoā rānei e rua. Kāo te whakamahi i ētahi rongoā i te wā e kai ana, i te taha rānei o te kai, te kai rānei i ētahi momo kai, nā te mea ka puta mai pea ngā mahi tahi. Ko te whakamahi i te waipiro, te tapeka rānei me ētahi rongoā ka puta mai pea ngā mahi tahi. Kōrero atu ki tō kaimahi hauora te whakamahi i tō rongoā me te kai, te waipiro, te tapeka rānei. Ko te whai i ētahi atu raruraru hauora ka pā pea ki te whakamahi i tēnei rongoā. Kia tino kī atu koe ki tō tākuta mēnā kei a koe ētahi atu raruraru hauora, ina koa: